Literature DB >> 24102019

Neo-adjuvant chemotherapy in early stage non-small cell lung cancer.

Ioannis Boukovinas1, Kosmas Tsakiridis, Paul Zarogoulidis, Nikolaos Machairiotis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Kostantinos Zarogoulidis.   

Abstract

Lung cancer treatment has evolved during the last decade from the non-specific cytotoxic drugs to targeted therapy. New diagnostic equipment such as the endobronchial ultrasound bronchoscopy and positron emission tomography has enhanced early lung cancer diagnosis. However; we still need additional novel biomarkers to assist the already used diagnostic techniques. Surgery is the still the best treatment for early lung cancer treatment. Several surgical techniques are being used based on the tumour location and cardiothoracic centre's experienced. There are however marginal situations where neo-adjuvant chemotherapy provides a "pre-step" for the patient. In the current work we will provide current data for the patients needing neo-adjuvant chemotherapy before proceeding to curative surgery.

Entities:  

Keywords:  Lung cancer; early stage; neo-adjuvant

Year:  2013        PMID: 24102019      PMCID: PMC3791501          DOI: 10.3978/j.issn.2072-1439.2013.07.36

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  7 in total

1.  Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  L Crinò; W Weder; J van Meerbeeck; E Felip
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Chemotherapy and surgery for operable NSCLC.

Authors:  Penelope A Bradbury; Frances A Shepherd
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

3.  Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.

Authors:  Katherine M W Pisters; Eric Vallières; John J Crowley; Wilbur A Franklin; Paul A Bunn; Robert J Ginsberg; Joe B Putnam; Kari Chansky; David Gandara
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

4.  Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.

Authors:  Alain Depierre; Bernard Milleron; Denis Moro-Sibilot; Sylvie Chevret; Elisabeth Quoix; Bernard Lebeau; Denis Braun; Jean-Luc Breton; Etienne Lemarié; Sylvie Gouva; Nadine Paillot; Jeanne-Marie Bréchot; Henri Janicot; François-Xavier Lebas; Philippe Terrioux; Jean Clavier; Pascal Foucher; Michel Monchâtre; Daniel Coëtmeur; Marie-Claude Level; Pascal Leclerc; François Blanchon; Jean-Michel Rodier; Luc Thiberville; Anne Villeneuve; Virginie Westeel; Claude Chastang
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

5.  Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

Authors:  Enriqueta Felip; Rafael Rosell; José Antonio Maestre; José Manuel Rodríguez-Paniagua; Teresa Morán; Julio Astudillo; Guillermo Alonso; José Manuel Borro; José Luis González-Larriba; Antonio Torres; Carlos Camps; Ricardo Guijarro; Dolores Isla; Rafael Aguiló; Vicente Alberola; José Padilla; Abel Sánchez-Palencia; José Javier Sánchez; Eduardo Hermosilla; Bartomeu Massuti
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 6.  A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer.

Authors:  Sarah Burdett; Lesley A Stewart; Larysa Rydzewska
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

Review 7.  Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.

Authors:  David Gilligan; Marianne Nicolson; Ian Smith; Harry Groen; Otilia Dalesio; Peter Goldstraw; Matthew Hatton; Penelope Hopwood; Christian Manegold; Franz Schramel; Hans Smit; Jan van Meerbeeck; Matthew Nankivell; Mahesh Parmar; Cheryl Pugh; Richard Stephens
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

  7 in total
  6 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  DDMC-p53 gene therapy with or without cisplatin and microwave ablation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger
Journal:  Onco Targets Ther       Date:  2015-05-20       Impact factor: 4.147

3.  A multifactoral analysis of 1452 patients for smoking sensation. An outpatient lab experience.

Authors:  Theodora Tsiouda; Paul Zarogoulidis; Dimitris Petridis; Nikolaos Pezirkianidis; Ioannis Kioumis; Lonny Yarmus; Haidong Huang; Qiang Li; Wolfgang Hohenforst-Schmidt; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Georgia Pitsiou; Theodoros Kontakiotis; Paraskevi Argyropoulou; George Kyriazis; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-05-10       Impact factor: 4.207

4.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

5.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

6.  Clinical significance of serum T helper 1/T helper 2 cytokine shift in patients with non-small cell lung cancer.

Authors:  Jun Li; Zhenhua Wang; Kai Mao; Xixi Guo
Journal:  Oncol Lett       Date:  2014-07-29       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.